A Staub, MD
Obstetrics & Gynecology · Dallas, TXNPI 1578565222
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,000 of the $14,688 with a category attached, or 68.1%. Ascend Therapeutics US, LLC accounts for 80.6% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2023 at $7,953 and has fallen 96.5% since, to $278 in 2025. Among obstetrics & gynecology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 224 payments — averaging $65.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ascend Therapeutics US, LLC$12K
- Astellas Pharma US Inc$437
- Exeltis, USA Inc.$274
- AbbVie$260
- Merck$224
- Pfizer$173
- plus $1K from 30 others
Across 110 payments — averaging $2847.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Exeltis, USA Inc.$254K
- Sage Therapeutics, LLC$34K
- Hologic Sales And Service, LLC$15K
- Bayer$10K
What the payments were for
- Consulting fees$1,51510%
- Speaking & faculty fees$10,00068%
- Food & beverage$2,97720%
- Education$1521%
- Gifts$440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ascend Therapeutics US, LLC | 78 | $11,842 |
| Astellas Pharma US Inc | 23 | $437 |
| Exeltis, USA Inc. | 14 | $274 |
| AbbVie | 13 | $260 |
| Merck | 10 | $224 |
| Pfizer | 10 | $173 |
| Organon | 7 | $148 |
| Gynesonics, Inc. | 3 | $136 |
| Mayne Pharma Commercial LLC | 6 | $129 |
| Bayer | 6 | $128 |
| Amgen | 5 | $92 |
| Millicent US Inc | 3 | $83 |
| Therapeuticsmd, Inc. | 5 | $76 |
| Sumitomo Pharma America, Inc. | 4 | $65 |
| Shield Therapeutics Inc | 3 | $64 |
| Exact Sciences | 4 | $60 |
| Aspira Women's Health Inc | 3 | $56 |
| AMAG Pharmaceuticals, Inc. | 4 | $52 |
| Vertical Pharmaceuticals, LLC | 2 | $41 |
| Integra Lifesciences Corporation | 2 | $35 |
| Channel Medsystems, Inc. | 1 | $33 |
| Johnson & Johnson | 2 | $28 |
| Duchesnay USA Incorporated | 2 | $25 |
| Innovation Technologies Inc | 1 | $24 |
| Agile Therapeutics, Inc. | 1 | $24 |
| Minerva Surgical, Inc | 1 | $23 |
| Hologic Sales And Service, LLC | 1 | $20 |
| Medtronic | 1 | $19 |
| Olympus America Inc. | 1 | $19 |
| Evofem Biosciences, Inc. | 1 | $16 |
| Coopersurgical, Inc. | 1 | $16 |
| Avion Pharmaceuticals | 1 | $14 |
| Pacira Pharmaceuticals Incorporated | 1 | $13 |
| Caldera Medical, Inc | 1 | $13 |
| Meditrina | 2 | $12 |
| Convatec Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,688 in reported general payments places this provider in the 95th percentile of 3,099 obstetrics & gynecology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PremarinEstrogens, Conjugated | 54 | $21,116 |
| PremproEstrogen,con/M-Progest Acet | 25 | $15,553 |
| ProgesteroneProgesterone, Micronized | 140 | $5,660 |
| Estradiol | 96 | $5,378 |
| Vivelle-DotEstradiol | 11 | $4,565 |
| EvamistEstradiol | 11 | $3,895 |
| Estradiol (Twice Weekly)Estradiol | 23 | $3,894 |
| Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet | 17 | $1,797 |
| Ibandronate Sodium | 36 | $1,086 |
| ValacyclovirValacyclovir Hcl | 20 | $500 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 11 | $120 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPremarin, Prempro | $173 | $36,66979 claims |
| Exeltis, USA Inc.Evamist | $274 | $3,89511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,099 obstetrics & gynecology providers in Texas.
Other obstetrics & gynecology in Dallas
- Dale StovallDallas$590K
- Quanita CrableDallas$176K
- Kamilia SmithDallas$119K
- Yolanda LawsonDallas$96K
- Patrick WeixDallas$96K
- David RogersDallas$44K
- Devin GarzaAustin$2M
- Shawn TassoneAustin$1.3M
- Karyn-Anne CumberbatchMissouri City$452K
- Robert AsgharianEl Paso$366K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.